After 9 Years in Trials, Roche’s Crenezumab Stalls Out
There were more than 140 experimental Alzheimer’s drugs in clinical trials as of the start of 2022. On the one hand, this number inspires…
There were more than 140 experimental Alzheimer’s drugs in clinical trials as of the start of 2022. On the one hand, this number inspires…
UPDATE: 3 March 2024, 8:35 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Vaccines are considered one of the greatest innovations in medical history. Immunizations help train the body’s immune system to recognize and respond to a…
UPDATE: 3 March 2024, 8:37 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
The lack of effective treatments for Alzheimer’s have spurred scientists to rethink the dominant approach to tackling the disease: the amyloid hypothesis. This hypothesis…
UPDATE: 3 March 2024, 8:27 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
UPDATE: 3 March 2024, 8:25 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
UPDATE: 3 March 2024, 8:18 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Scientists have their eyes set on spotting Alzheimer’s early. The earlier the disease can be diagnosed, the better the chance that a combination of…
Alzheimer’s is a notoriously difficult disease to identify with certainty. By the time a patient receives a diagnosis, its pathology in the brain is…
What’s the difference between treating Alzheimer’s symptoms and modifying the disease? Despite decades of research, the underlying cause of Alzheimer’s continues to evade scientists….
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Analysts had high hopes for anti-amyloid drug Aduhelm — the first Alzheimer’s treatment approved by the FDA in nearly two decades and the first…
Following the approval of the Alzheimer’s drug Aduhelm — and the litany of controversy surrounding it — one question that’s top of mind for…